Pioglitazone inhibits HIF-1α-dependent angiogenesis in rats by paracrine and direct effects on endothelial cells

Journal of Molecular Medicine

Volumn 92, Issue 5, 2014, Pages 497-507

  Dromparis, Peter ^a   Sutendra, Gopinath ^a   Paulin, Roxane ^a   Proctor, Spencer ^a   Michelakis, Evangelos D ^a   McMurtry, M Sean ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiogenesis; Diabetes; Mitochondria; Peripheral arterial disease; Thiazolidinediones

Indexed keywords

2 OXOGLUTARIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIGEL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PIOGLITAZONE; PLACEBO; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CAPILLARY DENSITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CT SPECT SCANNER; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN RESISTANCE; LIMB ISCHEMIA; LIMB PERFUSION; MALE; MICROVASCULAR ENDOTHELIAL CELL; MITOCHONDRION; MUSCLE CAPILLARY; NONHUMAN; PARACRINE SIGNALING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE; ULTRASOUND; ULTRASOUND SCANNER; ANIMAL; CELL LINE; DRUG EFFECTS; HINDLIMB; ISCHEMIA; METABOLISM; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE; ENDOTHELIAL CELLS; HINDLIMB; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISCHEMIA; MALE; MITOCHONDRIA; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PARACRINE COMMUNICATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899967621     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1115-0     Document Type: Article

References (35)

1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB et al (2006) ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113:e463-e654
2. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES et al (2011) Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 123:e18-e209
3. Abou-Zamzam AM Jr, Gomez NR, Molkara A, Banta JE, Teruya TH, Killeen JD, Bianchi C (2007) A prospective analysis of critical limb ischemia: factors leading to major primary amputation versus revascularization. Ann Vasc Surg 21:458-463 (Pubitemid 47030849)
4. Krempf M, Parhofer KG, Steg PG, Bhatt DL, Ohman EM, Rother J, Goto S, Pasquet B, Wilson PW (2010) Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol 105:667-671
5. Bundo M, Munoz L, Perez C, Montero JJ, Montella N, Toran P, Pera G (2010) Asymptomatic peripheral arterial disease in type 2 diabetes patients: a 10-year follow-up study of the utility of the ankle brachial index as a prognostic marker of cardiovascular disease. Ann Vasc Surg 24:985-993
6. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G et al (2008) Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300:197-208 (Pubitemid 351969304)
7. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106-1118
8. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-1289 (Pubitemid 41416583)
9. Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L (2009) Impact of peripheral arterial disease in patients with diabetes - results from PROactive (PROactive 11). Atherosclerosis 202:272-281
10. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA: J Am Med Assoc 298:1180-1188 (Pubitemid 47403104)
11. Xin X, Yang S, Kowalski J, Gerritsen ME (1999) Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274:9116-9121 (Pubitemid 29164719)
12. Sutendra G, Dromparis P, Kinnaird A, Stenson TH, Haromy A, Parker JM, McMurtry MS, Michelakis ED (2012) Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer. Oncogene. doi:10.1038/onc.2012.198
13. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W et al (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53:1052-1059 (Pubitemid 38436618)
14. Lopaschuk GD, Russell JC (1991) Myocardial function and energy substrate metabolism in the insulin-resistant JCR:LA corpulent rat. J Appl Physiol 71:1302-1308
15. Clark TA, Pierce GN (2000) Cardiovascular complications of non-insulin-dependent diabetes: the JCR:LA-cp rat. J Pharmacol Toxicol Methods 43:1-10
16. Van Oosterhout MF, Willigers HM, Reneman RS, Prinzen FW (1995) Fluorescent microspheres to measure organ perfusion: validation of a simplified sample processing technique. Am J Physiol 269:H725-H733
17. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Harry G et al (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37-51 (Pubitemid 46054520)
18. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D et al (2010) Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2:31ra34
19. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S (1998) Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 97:473-483 (Pubitemid 28090220)
20. Dromparis P, Sutendra G, Michelakis ED (2010) The role of mitochondria in pulmonary vascular remodeling. J Mol Med 88:1003-1010
21. Sutendra G, Dromparis P, Wright P, Bonnet S, Haromy A, Hao Z, McMurtry MS, Michalak M, Vance JE, Sessa WC et al (2011) The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med 3:88ra55
22. Motola D, Piccinni C, Biagi C, Raschi E, Marra A, Marchesini G, Poluzzi E (2012) Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf 35:315-323
23. Hankenson KD, Dishowitz M, Gray C, Schenker M (2011) Angiogenesis in bone regeneration. Injury 42:556-561
24. Scoditti E, Massaro M, Carluccio MA, Distante A, Storelli C, De Caterina R (2010) PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium. Cardiovasc Res 86:302-310
25. Kim KY, Cheon HG (2006) Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells. J Biol Chem 281:13503-13512
26. Aljada A, O'Connor L, Fu YY, Mousa SA (2008) PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis 11:361-367
27. Higuchi A, Ohashi K, Shibata R, Sono-Romanelli S, Walsh K, Ouchi N (2010) Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism. Arterioscler Thromb Vasc Biol 30:46-53
28. Murata T, Hata Y, Ishibashi T, Kim S, Hsueh WA, Law RE, Hinton DR (2001) Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol 119:709-717 (Pubitemid 32417377)
29. Gealekman O, Burkart A, Chouinard M, Nicoloro SM, Straubhaar J, Corvera S (2008) Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production. Am J Physiol Endocrinol Metab 295:E1056-E1064
30. Touyz RM, Schiffrin EL (2006) Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol 45:19-28 (Pubitemid 43963482)
31. Perez-Ortiz JM, Tranque P, Burgos M, Vaquero CF, Llopis J (2007) Glitazones induce astroglioma cell death by releasing reactive oxygen species from mitochondria: modulation of cytotoxicity by nitric oxide. Mol Pharmacol 72:407-417 (Pubitemid 47124121)
32. Garcia-Ruiz I, Solis-Munoz P, Fernandez-Moreira D, Munoz-Yague T, Solis-Herruzo JA (2013) Pioglitazone leads to an inactivation and disassembly of complex I of the mitochondrial respiratory chain. BMC Biol 11:88
33. Vine DF, Glimm DR, Proctor SD (2008) Intestinal lipid transport and chylomicron production: possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome. Atheroscler Suppl 9:69-76
34. Huang PH, Sata M, Nishimatsu H, Sumi M, Hirata Y, Nagai R (2008) Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed Pharmacother 62:46-52
35. Nagahama R, Matoba T, Nakano K, Kim-Mitsuyama S, Sunagawa K, Egashira K (2012) Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 32:2427-2434